Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOLENE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Moderate to severe pain management,Off-label: Drug-induced pulmonary edema,Off-label: Cough suppression
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Hepatic via CYP2D6 and CYP3A4; active metabolite morphine-6-glucuronide.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
20-30% bound to albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
1-2 L/kg; indicates extensive tissue distribution.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 50-60% (first-pass metabolism); Rectal: ~50%.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
GFR 30-50 m L/min: 50 mg every 6 hours; GFR 10-29 m L/min: 50 mg every 8 hours; GFR <10 m L/min: 50 mg every 12 hours.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg every 8 hours; Child-Pugh C: not recommended.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
1-2 mg/kg orally every 4-6 hours as needed; maximum 5 mg/kg per day or 200 mg per day, whichever is less.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Initiate at 25 mg every 6 hours; increase cautiously to 50 mg every 6 hours if needed; maximum 300 mg per day.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; interaction with alcohol or CNS depressants; risk of opioid-induced hyperalgesia.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Respiratory depression, particularly in elderly or debilitated; increased intracranial pressure; severe hypotension; adrenal insufficiency; serotonin syndrome; risk of seizures; severe hypotension; use in renal or hepatic impairment.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to morphine; severe respiratory depression; acute or severe bronchial asthma; gastrointestinal obstruction; concurrent MAOIs or within 14 days.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid alcohol consumption due to additive CNS depression and increased risk of propoxyphene toxicity. No specific food interactions documented; however, maintaining a balanced diet is recommended to support overall health.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
DOLENE (propoxyphene) is pregnancy category C; first trimester: no adequate human studies; potential risk of teratogenicity cannot be excluded; second and third trimesters: associated with neonatal respiratory depression, withdrawal syndrome, and fetal growth restriction with chronic use; avoid use during pregnancy unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Propoxyphene is excreted into breast milk; M/P ratio not well established; estimated infant dose is 1-2% of maternal weight-adjusted dose; potential for neonatal respiratory depression and sedation; use with caution; monitor infant for drowsiness and feeding difficulties.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Increased clearance and volume of distribution during pregnancy may require dose adjustment; no specific guidelines for propoxyphene; use lowest effective dose for shortest duration; consider avoiding due to lack of safety data and risk of neonatal withdrawal.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
DOLENE (propoxyphene) is a weak mu-opioid agonist with an active metabolite (norpropoxyphene) that has a long half-life (30-36 hours) and can accumulate, causing CNS and cardiac toxicity (QT prolongation, dysrhythmias). It is no longer marketed in many countries due to risk of fatal overdose, especially when combined with alcohol or other CNS depressants. Avoid in elderly, renal impairment, or patients with history of substance abuse. Consider ECG monitoring for QT prolongation in high-risk patients.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Do not exceed prescribed dose; overdose risk is high even at slightly elevated doses.,Avoid alcohol and all other CNS depressants (benzodiazepines, sedatives) while taking DOLENE.,Report any signs of toxicity: confusion, dizziness, slow heartbeat, fainting, seizures.,May cause dizziness or drowsiness; avoid driving or operating machinery.,Store safely out of reach of children and dispose of unused medication properly.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOLENE vs ACTIQ, answered by our medical review team.
DOLENE is a Opioid Analgesic that works by Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOLENE and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOLENE is: 50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOLENE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOLENE is classified as Category C. DOLENE (propoxyphene) is pregnancy category C; first trimester: no adequate human studies; potential risk of teratogenicity cannot be excluded; second and third trimesters: associa. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.